NEW YORK, August 19, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Petroleo Brasileiro Petrobras SA (NYSE: PBR), Ashland Inc. (NYSE: ASH), Alcoa Inc. (NYSE: AA), Air Products & Chemicals, Inc. (NYSE: APD) and Mosaic Co. (NYSE: MOS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5803-100free.

-- Petroleo Brasileiro Petrobras SA Research Reports

On August 8, 2014, Petroleo Brasileiro Petrobras SA (Petrobras) released its Q2 2014 and H1 2014 financial results. The Company reported Q2 2014 sales revenue of $36.9 billion, up 3.8% YoY. During the quarter, the Company's net income before finance income (expense), share of profit of equity-accounted investments, profit improved 23.9% QoQ to $4.0 billion, primarily due to the absence of a provision for the Voluntary Separation Incentive Plan ($1.0 billion), which took place in Q1 2014. The Company's Q2 2014 consolidated net income attributable to the shareholders of Petrobras came in at $2.2 billion or $0.18 per diluted share, compared to consolidated net income of $3.0 billion or $0.23 per diluted share in Q2 2013. The Company's H1 2014 sales revenue declined 0.7% YoY to $71.4 billion, while consolidated net income attributable to the shareholders of Petrobras stood at $4.5 billion, down 34.2% YoY. The full research reports on Petrobras are available to download free of charge at:

http://www.analystsreview.com/Aug-19-2014/PBR/report.pdf

-- Ashland Inc. Research Reports

On August 7, 2014, Ashland Inc. (Ashland) announced that the Company is planning to significantly expand its production capacity of its Klucel hydroxypropylcellulose (HPC) product line in Hopewell, Virginia. Ashland expects that the expansion will commence production in H2 2016. The Company informed that the above stated investment includes opening of Ashland's pharmaceutical center of excellence in Hyderabad, India, earlier this year; the pending expansion of Ashland's technical capabilities in Wilmington, Delaware; and the Polyplasdone(TM) crospovidone expansion in Texas City, Texas. David Neuberger, Vice President, Pharmaceutical Specialties, Ashland Specialty Ingredients, said, "Ashland is committed to the overall pharmaceutical market and has made a number of sizeable investments over the past two years to strengthen our position." Klucel HPC is a tablet binder and coating ingredient used in pharmaceutical applications and dietary supplements worldwide. The full research reports on Ashland are available to download free of charge at:

http://www.analystsreview.com/Aug-19-2014/ASH/report.pdf

-- Alcoa Inc. Research Reports

On August 13, 2014, Alcoa Inc.'s (Alcoa) stock moved up 0.31% from its previous day's close to end the trading session at $16.24, tracking gains in the S&P 500 index, which moved up 0.67% over the same trading session. Alcoa's stock opened the session at $16.22 and oscillated in the range of $16.13 - $16.29. A total of 9.40 million shares traded during the day, significantly lower than the previous day's trading volume of 15.23 million shares. Over the past one month, the stock has returned 0.81%, outperforming the S&P 500 which lost 1.54%, over the same period of time. The full research reports on Alcoa are available to download free of charge at:

http://www.analystsreview.com/Aug-19-2014/AA/report.pdf

-- Air Products & Chemicals, Inc. Research Reports

On August 11, 2014, Air Products & Chemicals, Inc. (Air Products) said that it is increasing prices of select Ancamide, Ancamine, Anquamine, Anquawhite, and Sunmide epoxy curing agents, as well as, select Nourybond adhesion promoters by up to $0.20 per kilogram, effective September 1, 2014. The main reason behind price hike is to recover higher raw material costs, including the recent price hikes on tetraethylenepentamine, triethylenetetramine, and polyetheramines. The full research reports on Air Products are available to download free of charge at:

http://www.analystsreview.com/Aug-19-2014/APD/report.pdf

-- Mosaic Co. Research Reports

On August 13, 2014, shares in Mosaic Co. (Mosaic) declined 1.74% from its previous day's close to end the trading session at $45.72. Mosaic's stock opened the session at $46.18 and fluctuated between $45.50 and $46.21. A total of 3.25 million shares changed hands during the day, higher than the previous day's trading volume of 1.51 million shares. The stock has a 52-week high of $51.25 and a 52-week low of $40.85. Over the past 12-months, the stock has returned 4.50%. The full research reports on Mosaic are available to download free of charge at:

http://www.analystsreview.com/Aug-19-2014/MOS/report.pdf

-- About Analysts Review We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

=============== EDITOR'S NOTES: ===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Analysts Review